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To the editor, 
 
We thank Löwe et al for their interest in our recent study1 and the opportunity to offer 
further clarifications. Although we acknowledge the interest of the question raised by 
Löwe et al, we think they miss the main rationale and research question of our 
analysis,1 namely to provide the only randomised controlled trial (RCT) evidence in 
primary prevention for lipid-lowering among individuals with low-density lipoprotein-
cholesterol (LDL-C) >190 mg/dL, a level consistent with inherited or genetic 
dyslipidaemia (primary hypercholesterolaemia). Current guidelines cite that statins are 
likely to be beneficial for such patients, but also acknowledge that there are no direct 
RCT evidence to support these recommendations. Given ethical concerns that would 
be posed by giving placebo to patients with LDL-C >190 mg/dL, the WOSCOPS data 
offers the only option to answer this question.1 The authors cite that the unanswered 
question is “will providing statins to people at low risk of atherosclerosis 
cardiovascular disease (ASCVD) lower their risk even more?” This has been at least 
partly answered by the HOPE-3 trial2 where the annual cardiovascular disease event 
rate was 0.7% per year in the placebo group and rosuvastatin reduced cardiovascular 
risk by about one quarter; however, the patients in that trial did not have elevated 
LDL-C as in WOSCOPS. 
We disagree with comments regarding The Pooled Cohorts Equation (PCE), which we 
should point out has been validated and outperformed SCORE and other approaches in 
two European populations and performed at least as well as SCORE in the EPIC-
NORFOLK study.,3-5 In addition, using the MESA cohort for the evaluation of the 
predictive utility of the PCE, as in the paper referenced by Löwe et al, has raised 
concerns as outlined by Goff et al.6 Even with the high proportion of smokers in our 
analysis, this exposure was incorporated, and so accounted for, in the risk equation. If 
treatment decisions were made on the basis of a risk prediction tool rather than LDL-C 
levels, then statin therapy would have been withheld in about 67% of our cohort with 
LDL-C >190 mg/dL, in whom the 10-year predicted risk was <7.5%, in contrast to the 
actual observed risk of approximately 15%.1 Individuals with primary severe 
hypercholesterolemia are likely to have an underlying genetic component to their LDL-
C elevation and, therefore, an integrated lifetime exposure to high LDL-C that is not 
reflected in a risk score algorithm; this aligns with the concept of cumulative LDL-C 
exposure over time as a determinant of the progression and risk of ASCVD (“LDL-C 
levels x years”),7 which is inaccurately captured using a single LDL-C level measurement 
at one specific time-point. All this suggests that in cases of primary severe elevations of 
LDL-C conventional risk prediction tools may underestimate cardiovascular risk, and 
our findings suggest that risk prediction tools should not be routinely used when LDL-C 
is >190 mg/dL (primary elevations), as already stated in guidelines. Thus our findings 
strengthen current guideline recommendations. Statin therapy in the same population 
lowered the 10-year risk to <10%;1 thus, among populations with primary LDL-C >190 
mg/dL we believe that such individuals are at elevated lifetime risk and that early 
initiation of statins (small reductions maintained over time) would translate into 
meaningful benefits, as also suggested by our extended follow-up data.1 While 
guidelines are recommendations and individual patients should be considered on an 
individual basis for prescription of therapy, including those with LDL-C >190 mg/dL, it 
must also be noted that using a risk scoring system to deny treatment to patients that 
may benefit of it would not be best practice. Our study provides a solid evidence-base 
for the clinician who decides on the basis of a full assessment including other risk 
factors, family history, querying familial hypercholesterolemia, or, in the future, a 
potential genetic score to decide on statin prescription. 
Finally, as we already acknowledged in the Source of Funding section of our article,1 
the present analyses were partly funded by a grant from Sanofi to Imperial College 
London; this grant was for statistical analysis, which was performed, independently of 
sponsors, at Glasgow University where the WOSCOPS database is kept. For the 
avoidance of doubt, we provide assurance that the sponsors did not have any role nor 
influence the analysis presented in the article. 
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